MHO IB-MEDIATED MYELIN-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR MULTIPLE SCLEROSIS AND MOG ANTIBODY DISEASE
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class lb molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease and MOG antibody p...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BRÜNNERT, Daniela WISCHHUSEN, Jörg AHSAN, Fadhil BRUTTEL, Valentin |
| description | The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class lb molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class lb molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica.
La présente invention concerne des utilisations thérapeutiques de molécules du complexe majeur d'histocompatibilité (CMH) humain non classique (également nommées molécules du CMH de classe lb) en combinaison avec des antigènes peptidiques associés à la myéline pour le traitement de la sclérose en plaques (SEP), de la maladie associée aux anticorps anti-MOG et de la neuromyélite optique positive aux anticorps anti-MOG. L'invention concerne plus particulièrement des polypeptides recombinants comprenant des antigènes peptidiques et un ou plusieurs domaines d'une molécule de classe lb du CMH non classique. L'invention concerne également des procédés de production de tels polypeptides recombinants, des compositions pharmaceutiques les comprenant, ainsi que leurs utilisations pour le traitement de la sclérose en plaques (SEP), de la maladie associée aux anticorps anti-MOG et de la neuromyélite optique positive aux anticorps anti-MOG. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023180546A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023180546A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023180546A13</originalsourceid><addsrcrecordid>eNqNzM8KgkAQgHEvHaJ6h4HOgtofuq465sDujuyshSeR2E5RgtHz56EH6PRdfnzL6GNqBspjgyUpjyWYDjXZWBosqKICyJjWsrRN41CE2IISUGD5ghq8Q-UNWg8VOzCt9tRoBCk0OhaaoZ2PfJ7rKeeyg5IEleA6WtyHxxQ2v66ibYW-qOMwvvowjcMtPMO7v3KWZLv0lBz2R5Xu_lNfJtw6ig</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MHO IB-MEDIATED MYELIN-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR MULTIPLE SCLEROSIS AND MOG ANTIBODY DISEASE</title><source>esp@cenet</source><creator>BRÜNNERT, Daniela ; WISCHHUSEN, Jörg ; AHSAN, Fadhil ; BRUTTEL, Valentin</creator><creatorcontrib>BRÜNNERT, Daniela ; WISCHHUSEN, Jörg ; AHSAN, Fadhil ; BRUTTEL, Valentin</creatorcontrib><description>The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class lb molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class lb molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica.
La présente invention concerne des utilisations thérapeutiques de molécules du complexe majeur d'histocompatibilité (CMH) humain non classique (également nommées molécules du CMH de classe lb) en combinaison avec des antigènes peptidiques associés à la myéline pour le traitement de la sclérose en plaques (SEP), de la maladie associée aux anticorps anti-MOG et de la neuromyélite optique positive aux anticorps anti-MOG. L'invention concerne plus particulièrement des polypeptides recombinants comprenant des antigènes peptidiques et un ou plusieurs domaines d'une molécule de classe lb du CMH non classique. L'invention concerne également des procédés de production de tels polypeptides recombinants, des compositions pharmaceutiques les comprenant, ainsi que leurs utilisations pour le traitement de la sclérose en plaques (SEP), de la maladie associée aux anticorps anti-MOG et de la neuromyélite optique positive aux anticorps anti-MOG.</description><language>eng ; fre</language><subject>CHEMISTRY ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230928&DB=EPODOC&CC=WO&NR=2023180546A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230928&DB=EPODOC&CC=WO&NR=2023180546A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BRÜNNERT, Daniela</creatorcontrib><creatorcontrib>WISCHHUSEN, Jörg</creatorcontrib><creatorcontrib>AHSAN, Fadhil</creatorcontrib><creatorcontrib>BRUTTEL, Valentin</creatorcontrib><title>MHO IB-MEDIATED MYELIN-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR MULTIPLE SCLEROSIS AND MOG ANTIBODY DISEASE</title><description>The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class lb molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class lb molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica.
La présente invention concerne des utilisations thérapeutiques de molécules du complexe majeur d'histocompatibilité (CMH) humain non classique (également nommées molécules du CMH de classe lb) en combinaison avec des antigènes peptidiques associés à la myéline pour le traitement de la sclérose en plaques (SEP), de la maladie associée aux anticorps anti-MOG et de la neuromyélite optique positive aux anticorps anti-MOG. L'invention concerne plus particulièrement des polypeptides recombinants comprenant des antigènes peptidiques et un ou plusieurs domaines d'une molécule de classe lb du CMH non classique. L'invention concerne également des procédés de production de tels polypeptides recombinants, des compositions pharmaceutiques les comprenant, ainsi que leurs utilisations pour le traitement de la sclérose en plaques (SEP), de la maladie associée aux anticorps anti-MOG et de la neuromyélite optique positive aux anticorps anti-MOG.</description><subject>CHEMISTRY</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNzM8KgkAQgHEvHaJ6h4HOgtofuq465sDujuyshSeR2E5RgtHz56EH6PRdfnzL6GNqBspjgyUpjyWYDjXZWBosqKICyJjWsrRN41CE2IISUGD5ghq8Q-UNWg8VOzCt9tRoBCk0OhaaoZ2PfJ7rKeeyg5IEleA6WtyHxxQ2v66ibYW-qOMwvvowjcMtPMO7v3KWZLv0lBz2R5Xu_lNfJtw6ig</recordid><startdate>20230928</startdate><enddate>20230928</enddate><creator>BRÜNNERT, Daniela</creator><creator>WISCHHUSEN, Jörg</creator><creator>AHSAN, Fadhil</creator><creator>BRUTTEL, Valentin</creator><scope>EVB</scope></search><sort><creationdate>20230928</creationdate><title>MHO IB-MEDIATED MYELIN-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR MULTIPLE SCLEROSIS AND MOG ANTIBODY DISEASE</title><author>BRÜNNERT, Daniela ; WISCHHUSEN, Jörg ; AHSAN, Fadhil ; BRUTTEL, Valentin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023180546A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><toplevel>online_resources</toplevel><creatorcontrib>BRÜNNERT, Daniela</creatorcontrib><creatorcontrib>WISCHHUSEN, Jörg</creatorcontrib><creatorcontrib>AHSAN, Fadhil</creatorcontrib><creatorcontrib>BRUTTEL, Valentin</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BRÜNNERT, Daniela</au><au>WISCHHUSEN, Jörg</au><au>AHSAN, Fadhil</au><au>BRUTTEL, Valentin</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MHO IB-MEDIATED MYELIN-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR MULTIPLE SCLEROSIS AND MOG ANTIBODY DISEASE</title><date>2023-09-28</date><risdate>2023</risdate><abstract>The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class lb molecules) in combination with myelin-associated peptide antigens for the treatment of multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class lb molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating multiple sclerosis (MS), MOG antibody disease and MOG antibody positive neuromyelitis optica.
La présente invention concerne des utilisations thérapeutiques de molécules du complexe majeur d'histocompatibilité (CMH) humain non classique (également nommées molécules du CMH de classe lb) en combinaison avec des antigènes peptidiques associés à la myéline pour le traitement de la sclérose en plaques (SEP), de la maladie associée aux anticorps anti-MOG et de la neuromyélite optique positive aux anticorps anti-MOG. L'invention concerne plus particulièrement des polypeptides recombinants comprenant des antigènes peptidiques et un ou plusieurs domaines d'une molécule de classe lb du CMH non classique. L'invention concerne également des procédés de production de tels polypeptides recombinants, des compositions pharmaceutiques les comprenant, ainsi que leurs utilisations pour le traitement de la sclérose en plaques (SEP), de la maladie associée aux anticorps anti-MOG et de la neuromyélite optique positive aux anticorps anti-MOG.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2023180546A1 |
| source | esp@cenet |
| subjects | CHEMISTRY METALLURGY ORGANIC CHEMISTRY PEPTIDES |
| title | MHO IB-MEDIATED MYELIN-SPECIFIC IMMUNOSUPPRESSION AS A NOVEL TREATMENT FOR MULTIPLE SCLEROSIS AND MOG ANTIBODY DISEASE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A09%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BR%C3%9CNNERT,%20Daniela&rft.date=2023-09-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023180546A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |